Industry News
Study Demonstrates One Administration Of Synvisc Improves Osteoarthritis Pain
December 1, 2006
Genzyme Corporation (Nasdaq: GENZ) announced today that preliminary results from a new study indicate that patients using Synvisc (hylan G-F 20) through a single-dose regimen achieved a statistically significant improvement in pain from osteoarthritis of the knee over 26 weeks compared with those using placebo. Story
Interventional Spine, Inc. Announces CE Mark Approval of Its Percutaneous Dynamic Stabilization for the Treatment of Spinal Disease
November 30, 2006
Interventional Spine, Inc. (formerly Triage Medical®, Inc.) today announced its European notified body has granted CE Mark approval for the Company's Percutaneous Dynamic Stabilization ("PDS") System for the early-stage treatment of spinal disorders. This approval will allow the Company to begin marketing the PDS in European Union countries and other countries around the world that recognize the CE Mark approval process. Story
FDA Panel Backs Celebrex for Kids With Arthritis
November 29, 2006
A U.S. Food and Drug Administration advisory panel recommended Wednesday that use of the painkiller Celebrex be expanded to treat children with juvenile rheumatoid arthritis. Story
New Study Gives Hope for Fibromyalgia Sufferers
November 29, 2006
A new study just released by NuScience Corporation shows a significant decrease in some of the symptoms related to Fibromyalgia. The study done by Professor Roberto Marcolongo at the University of Siena, Italy, looked at the efficacy of treating patients diagnosed with Fibromyalgia with a specific blend of 129 nutrients called CELLFOOD. Story
More Than 1,000 Patients Receive The Arthrosurface Product For The Great Toe
November 28, 2006
Hallux Rigidus is a disease that affects the head of the metatarsal often resulting in a painful and stiff first toe joint. This pain and stiffness can severely impact patients to the point where their daily activities become difficult and debilitating. HemiCAP provides a better alternative to joint fusion, reports Arthrosurface. Story
TranS1’s AxiaLIF™ Honored as Most Promising New Product in 2006
November 16, 2006 10:00 AM Eastern Time
TranS1, Inc., a medical device company focused on developing minimally invasive procedures for the treatment of lower back pain, announced today that its ground-breaking AxiaLIF™ product was awarded “The Most Promising New Product Award” at the 13th Annual Phoenix Conference, a medical device and diagnostics conference for chief executive officers. Story
Bayer Responds to Publication of the Alzheimer's Disease Anti-Inflammatory Prevention
November 16, 2006
In response to today's publication of the ADAPT manuscript [full text], Bayer's position is that the data presented from the trial must be reviewed in the context of the overwhelming body of scientific evidence supporting the safety of naproxen. Bayer continues to stand behind naproxen, the active ingredient in ALEVE, with its thirty-year history of clinical study and patient use. Story
New analysis shows Kadian alleviates chronic moderate-to-severe non-malignant neck pain
November 15, 2006
Patients with moderate-to-severe chronic neck pain who had inadequate relief on previous analgesic regimens attained improvements in pain, sleep and quality of life when treated with the long-acting opioid analgesic KADIAN® (morphine sulfate extended-release) Capsules. These study results were highlighted in a presentation today at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Meeting in Honolulu. Story
Data Shows ENBREL Provides Sustained Clinical Improvements For People With Ankylosing Spondylitis For Up To Three Years
November 15, 2006
Data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel(R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. Story
Merck Wins Federal VIOXX® Product Liability Case
November 15, 2006
Afederal court jury in New Orleans found in favor of Merck, rejecting a claim that VIOXX caused the 2003 heart attack of a then 61-year-old Utah man. “The jury determined that Merck acted appropriately in the development and marketing of VIOXX and that VIOXX did not substantially contribute to Mr. Mason's heart attack,” said Phil Beck, of the law firm of Bartlit Beck, Merck’s lead trial lawyer in the case, Mason v. Merck. Story
Lyrica May Relieve Fibromyalgia Pain
November 14, 2006
A new study suggests that the seizure drug Lyrica may improve pain in people with fibromyalgia and that these improvements may last at least six months. Story
New Safety Data Presented on Osteoarthritis Pain Medication Lumiracoxib
November 13, 2006
Novartis announced today that lumiracoxib, an investigational oral selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID), reduced the incidence of ulcer complications in both younger and older patients. Another subanalysis showed that NSAID treatment for four weeks significantly increased blood pressure compared to lumiracoxib. These new post-hoc subanalyses are being presented at the 70th annual meeting of the American College of Rheumatology (ACR). Story
Two-Year Data for Abatacept Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
November 9, 2006
Bristol-Myers Squibb Company (NYSE: BMY) today announced that
two-year data from three Phase III pivotal trials demonstrate the
long-term efficacy of abatacept in adult patients with moderate to
severe rheumatoid arthritis (RA) who have had an inadequate response
to one or more disease-modifying anti-rheumatic drugs. Story
Cephalon Announces Positive Results For FENTORA(TM) (fentanyl Buccal Tablet) For Breakthrough Pain In Patients With Chronic Low Back Pain
October 12, 2006
Cephalon, Inc. today announced that data from a Phase 3 clinical trial of FENTORA (fentanyl buccal tablet) demonstrate efficacy in the management of breakthrough pain in opioid-tolerant patients with chronic low back pain. Story
Cephalon Receives FDA Approval of FENTORA(TM) (fentanyl buccal tablet) for the Management of Breakthrough Pain in Patients with Cancer
September 25, 2006
Cephalon, Inc. (Nasdaq: CEPH - News) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market FENTORA(TM) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Story
|
